The New York Heart Association’s Functional Classification system, a century-old clinical standard, is the bedrock for stratifying heart failure severity in trials and clinical practice.
This framework, introduced in 1928 by the Criteria Committee of the New York Heart Association and refined through nine subsequent editions, assigns patients with established heart failure into one of four dynamic classes based on the workload that provokes symptoms.
The classification is a clinician-assigned scale that evaluates how severely a patient’s cardiac pathology restricts ordinary daily physical exertion. The classes are defined by the level of physical activity that triggers symptoms such as fatigue, palpitation, or dyspnea.
- NYHA Class I (No Limitation): Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. This class corresponds to a functional capacity of ≥ 7.0 METs or a 6-Minute Walk Distance (6MWD) typically greater than 450 meters.
- NYHA Class II (Slight Limitation): Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest, but ordinary activity, such as climbing two flights of stairs or walking uphill, results in symptoms. This class correlates with 5.0 to 6.9 METs and a 6MWD typically between 300 and 450 meters.
- NYHA Class III (Marked Limitation): Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest, but less than ordinary activity, such as walking 1–2 blocks on level ground, causes symptoms. This class is sometimes subdivided in clinical trials into IIIa and IIIb. It corresponds to 2.0 to 4.9 METs and a 6MWD typically between 150 and 300 meters.
- NYHA Class IV (Severe Limitation / Symptoms at Rest): Patients with cardiac disease resulting in an inability to carry on any physical activity without discomfort. Symptoms may be present even at rest and increase with any activity. This class has a functional capacity of < 2.0 METs and a 6MWD typically less than 150 meters, or the patient is unable to walk.
A foundational principle is that the NYHA Functional Classes must be distinguished from other classification systems. The NYHA system is dynamic and symptom-based, tracking how a patient feels with activity. In contrast, the AHA/ACC/HFSA Heart Failure Stages (A, B, C, and D) are unidirectional and structural, tracking the progression of heart disease over a patient’s lifetime. The Killip Classification (Classes I–IV) is specific to acute myocardial infarction.
The NYHA classification is subjective and based on a clinician’s assessment of a patient’s symptom burden with ordinary physical activity. While it is a global clinical standard used in clinics, remote patient monitoring, and FDA trials, its limitations are clear. It does not replace objective assessment methods such as perfusion, biomarkers, or hemodynamic data.
Selecting the correct NYHA class prevents staging errors in electronic health record documentation and clinical trial eligibility screening. The system’s complementary nature with the AHA/ACC/HFSA stages allows for a more comprehensive evaluation of a patient’s heart failure status.
